# Acceptance and Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) Vaccination in Systemic Sclerosis Patients Treated by Autologous Hematopoietic Stem Cell Transplantation

> **NCT05960058** · — · UNKNOWN · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 72 (estimated)

## Conditions studied

- Systemic Sclerosis
- SARS-CoV 2 Vaccination

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT05960058
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-07
- **Primary completion:** 2024-07
- **Final completion:** 2024-07
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2023-07-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05960058

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05960058, "Acceptance and Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-COV-2) Vaccination in Systemic Sclerosis Patients Treated by Autologous Hematopoietic Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05960058. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*